文献速递心律失常

基于生物标志物的房颤患者缺血性卒中预测模型

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

在26452例接受DOAC或华法林治疗的房颤患者中,评估基于年龄、生物标志物和临床病史的ABC-AF卒中风险评分,并开发改良ABC-AF-istroke评分预测总卒中和缺血性卒中。ABC-AF评分区分度优于ATRIA和CHA2DS2-VASc评分,校准良好,决策曲线分析显示净获益。

要点

  • ABC-AF卒中评分在房颤患者中区分度优于ATRIA和CHA2DS2-VASc评分。
  • 改良ABC-AF-istroke评分对缺血性卒中/SEE的区分度亦优于传统评分。
  • ABC-AF评分校准良好,决策曲线分析显示对卒中预防决策有净获益。

核心结论

  • 基于生物标志物的ABC-AF风险评分校准良好,区分度优于临床风险评分,为房颤患者卒中预防治疗提供有意义的决策支持。

研究设计与样本

  • 在26452例接受直接口服抗凝药或华法林治疗的房颤患者中,使用年龄、卒中临床病史、N末端B型利钠肽前体和肌钙蛋白水平计算ABC-AF-卒中评分和改良ABC-AF-istroke评分。

主要发现

  • 随访期间共756例卒中或系统性栓塞,其中534例缺血性卒中/系统性栓塞。
  • 总卒中/系统性栓塞的区分度:ABC-AF-卒中评分C-index为0.667(95%CI:0.648-0.687),优于ATRIA的0.632(95%CI:0.612-0.652)和CHA2DS2-VASc的0.614(95%CI:0.594-0.633),两者P均<0.001。
  • 缺血性卒中/系统性栓塞的区分度:ABC-AF-istroke评分C-index为0.677(95%CI:0.654-0.700),优于ATRIA的0.642(95%CI:0.618-0.666)和CHA2DS2-VASc的0.624(95%CI:0.601-0.647),两者P均<0.001。
  • ABC-AF-卒中评分对总卒中和缺血性卒中显示良好校准,结果在相关亚组中一致。
  • 决策曲线分析显示在卒中预防决策阈值方面有净获益。

临床怎么用

  • 对于房颤患者,可考虑使用基于生物标志物的ABC-AF风险评分辅助评估卒中和缺血性卒中风险,以支持卒中预防治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with atrial fibrillation (AF) the risk of ischemic stroke is central to recommendations for stroke-prevention treatment. OBJECTIVES: The authors evaluated the biomarker-based Age, Biomarkers, Clinical history (ABC)-AF-stroke risk score and developed a modified ABC-AF-istroke risk score for prediction of respectively total and ischemic stroke in patients with AF. METHODS: In 26,452 patients with AF assigned to direct oral anticoagulants (DOACs) or warfarin, information on age, clinical history of stroke, and levels of N-terminal pro B-type natriuretic peptide and troponin were used for calculation of the ABC-AF-stroke score and the modified ABC-AF-istroke score. RESULTS: During follow-up, there were 756 cases with stroke or systemic embolism (SEE) including 534 with ischemic stroke/SEE. The discrimination of total stroke/SEE was superior for the ABC-AF-stroke score, C-index (0.667 [95% CI: 0.648-0.687]), compared with 0.632 (95% CI: 0.612-0.652) for the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) and 0.614 (95% CI: 0.594-0.633) for the CHA2DS2-VASc score (P < 0.001 for both). The results were similar for ischemic stroke/SEE with C-index for ABC-AF-istroke 0.677 (95% CI: 0.654-0.700) compared with 0.642 (95% CI: 0.618-0.666) for the ATRIA and 0.624 (95% CI: 0.601-0.647) for the CHA2DS2-VASc score (P < 0.001 for both). The ABC-AF-stroke scores showed good calibration for total and ischemic stroke. Results were consistent in relevant subgroups. Decision curve analyses showed a net benefit concerning stroke-prevention decision thresholds. CONCLUSIONS: The biomarker-based ABC-AF risk scores for the risk of total and ischemic stroke were well calibrated, showed better discrimination than clinical risk scores in predicting total and ischemic stroke, and provided meaningful decision support for stroke-prevention treatments in patients with AF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Wallentin, Lindbäck, Hijazi, et al. Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2025. PMID: 40107814. doi:10.1016/j.jacc.2024.11.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。